We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.36 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDDDD
RNS Number : 9441Y
4d Pharma PLC
14 September 2020
14 September 2020
4D pharma plc
(the "Company" or "4D")
Block Listing Six Monthly Return
Name of applicant: 4D Pharma plc Name of scheme: Block Admission for February 2020 warrants -------------------------------------------------------------- Period of return: From: 10 March 2020 To: 9 September 2020 ---------------------- ----------------------- -------- --------------------------- Number of securities originally admitted at date of 22,000,000 Ordinary Shares of 0.25p each on 10 March 2020 admission: -------------------------------------------------------------- Balance of unallotted securities under scheme(s) from 22,000,000 Ordinary shares previous return: -------------------------------------------------------------- Plus: The amount by which the block scheme(s) has 0 Ordinary shares been increased since the date of the last return (if any increase has been applied for): -------------------------------------------------------------- Less: Number of securities issued/allotted under 0 Ordinary shares scheme(s) during period: -------------------------------------------------------------- Equals: Balance under scheme(s) not yet 22,000,000 Ordinary shares issued/allotted at end of period: -------------------------------------------------------------- Name of contact: Duncan Peyton Telephone number of contact: Company Secretary (0113 895 0130) ----------------------------------
Contact Information:
4D
Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000
Aubrey Powell / Justin McKeegan / Iqra Amin (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson / Phil Walker
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRBUGDCIBBDGGS
(END) Dow Jones Newswires
September 14, 2020 11:30 ET (15:30 GMT)
1 Year 4d Pharma Chart |
1 Month 4d Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions